1334 related articles for article (PubMed ID: 34161051)
21. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
22. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
23. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
24. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
25. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
Ahmadzadehfar H; Wegen S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Wei X; Schlenkhoff C; Hauser S; Essler M
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1448-1454. PubMed ID: 28488028
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of
Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120
[No Abstract] [Full Text] [Related]
27. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
28. [
Satapathy S; Sahoo RK; Bal C
J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of [
Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
[No Abstract] [Full Text] [Related]
30.
Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
[TBL] [Abstract][Full Text] [Related]
31.
Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
[TBL] [Abstract][Full Text] [Related]
32.
Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L
J Nucl Med; 2022 Apr; 63(4):560-566. PubMed ID: 34326127
[No Abstract] [Full Text] [Related]
33. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
34. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
35. Real-world Outcomes and Predictive Biomarkers for
Kafka M; Horninger A; di Santo G; Virgolini I; Neuwirt H; Unterrainer LM; Kunte SC; Deiss E; Paffenholz P; Heidenreich A; Rasul S; Einspieler H; Shariat SF; Rajwa P; Dozauer R; Tsaur I; Medlock E; Rölz N; Rausch S; la Fougère C; Trautwein N; Roesch MC; Merseburger AS; Zattoni F; Sepulcri M; Ladurner M; Bektic J; Gandaglia G; Horninger W; Heidegger I
Eur Urol Oncol; 2024 Jun; 7(3):421-429. PubMed ID: 37604763
[TBL] [Abstract][Full Text] [Related]
36. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
37. Single-dose
Aggarwal R; Starzinski S; de Kouchkovsky I; Koshkin V; Bose R; Chou J; Desai A; Kwon D; Kaushal S; Trihy L; Rastogi M; Ippisch R; Aslam M; Friedlander T; Feng F; Oh D; Cheung A; Small E; Evans M; Fong L; Hope TA
Lancet Oncol; 2023 Nov; 24(11):1266-1276. PubMed ID: 37922930
[TBL] [Abstract][Full Text] [Related]
38. Preparation of
Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T
Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436
[TBL] [Abstract][Full Text] [Related]
39. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
40. Renal and Multiorgan Safety of
Herrmann K; Rahbar K; Eiber M; Sparks R; Baca N; Krause BJ; Lassmann M; Jentzen W; Tang J; Chicco D; Klein P; Blumenstein L; Basque JR; Kurth J
J Nucl Med; 2024 Jan; 65(1):71-78. PubMed ID: 38050121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
